Tamekia Downs, in Bastrop, LA - Behavior Analyst

Tamekia Downs, is a Behavior Analyst based in Bastrop, Louisiana. Tamekia Downs is licensed to practice in * (Not Available) (license number ) and her current practice location is 644 E Jefferson Ave, Bastrop, Louisiana. She can be reached at her office (for appointments etc.) via phone at (318) 239-3862.

NPI number for Tamekia Downs is 1871925743 and her current mailing address is 644 E Jefferson Ave, Bastrop, Louisiana. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1871925743.

Contact Information

	Tamekia Downs,
	644 E Jefferson Ave, Bastrop, LA 71220-4619
	(318) 239-3862
	(318) 239-3862

Healthcare Provider's Profile

Full Name	Tamekia Downs
Gender	Female
Speciality	Behavior Analyst
Location	644 E Jefferson Ave, Bastrop, Louisiana
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1871925743
Provider Enumeration Date: 08/02/2013
Last Update Date: 03/23/2016

Medical Identifiers

Medical identifiers for Tamekia Downs such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1871925743	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	(* (Not Available))	Secondary
103K00000X	Behavior Analyst	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Tamekia Downs is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Tamekia Downs, 644 E Jefferson Ave, Bastrop, LA 71220-4619 Ph: (318) 239-3862	Tamekia Downs, 644 E Jefferson Ave, Bastrop, LA 71220-4619 Ph: (318) 239-3862

News Archive

Japanese MHLW approves Sosei's Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

Researchers reveal how tumor cells disrupt circadian rhythm to survive

Tumor cells use the unfolded protein response to alter circadian rhythm, which contributes to more tumor growth, Hollings Cancer Center researchers at the Medical University of South Carolina find.

UC Davis leads a consortium to develop new treatments for spinal cord injuries

Engineers at the University of California, Davis, will lead a consortium of universities, biomedical startups and nonprofit organizations to develop interventions for spinal cord injuries that can be applied within days of injury to improve long-term outcomes.

Rifampin kinetics poor in children

Rifampin (RMP), a first-line antituberculosis drug, reaches serum concentrations well below suggested lower limits when a standard dose of 8-12mg/kg body weight is given to children.

Exposure to air pollution in the womb can lead to high blood pressure in childhood

Children who were exposed to higher levels of air pollution during the third trimester of their mother's pregnancy had a higher risk of elevated blood pressure in childhood, according to new research in the American Heart Association's journal Hypertension.

Tamekia Downs, - in Bastrop, LA